Due to advances in medicine and diagnostics, more patients are surviving cancer than ever before. Today two out of three cancer patients live at least five years after a cancer diagnosis, up from roughly one out of two in the 1970s (CancerProgress.net).
Predictive biomarkers for personalized and precision medicine of cancer patients is the next leap forward in improving the quality of care of cancer patients (Personalized Medicine at FDA). Advances in our ability to identify biomarkers for predicting cancer patients' treatment response is the tool used for tailoring personalized treatment regimens. Precise treatment increases cancer patients' survival rate and improves patients' overall quality of life.
Curewize's technology measures the level of microRNA in biofluids. Physicians can tailor the optimal type of treatment for the cancer patient according to the microRNA test results. MicroRNA are considered to be ideal prognostic and diagnostic biomarkers due to their stability in biofluids and association with almost all cancers. Curewize pipeline includes microRNA lab tests for precision medicine of several cancers.
Curewize lead product is ProALL for treatment decision of Acute Lymphoblastic Leukemia (ALL) patients. Current practice uses lab tests for deciding ALL treatment regimen, so patients are treated with the best treatment possible with the least amount of detrimental side effects. Oncologist incorporate personalized medicine in ALL treatment protocols due to the sensitivty of young cancer patients to treatment side-effects. Seventy-five percent of young cancer patients that survive, face lifelong challenges including secondary cancers, bone marrow depression, lung damage, heart damage, liver damage, hearing loss, cognitive problems, infertility, weight problems and shorter lifespan. ProALL is a groundbreaking lab test that can improve personalized treatment decisions of ALL patients.